Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 4Terminated 3

Sponsor Class

NIH 9INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × alvocidib × Clear all
NCT02520011 2023-11-15

Alvocidib Biomarker-driven Phase 2 AML Study

Sumitomo Pharma America, Inc.

Phase 2 Terminated
104 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03593915 2023-11-09

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Sumitomo Pharma America, Inc.

Phase 1/2 Terminated
20 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelomonocytic, Chronic

NCT03969420 2023-11-09

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

Sumitomo Pharma America, Inc.

Phase 2 Terminated
11 enrolled 10 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡